Primer Capital
VC Fund
Moscow, Russian Federation
PRIMER CAPITAL is a venture capital fund focusing on investments in companies engaged in development of promising biotech and medical products for various pharmaceutical sectors.Our qualified managing Team is interested in a high-quality selection of projects that form our portfolio. Our team of qualified consultants and Scientific AdvisoryBoard consisting of top experts in various medical, biopharmaceutical, and business fields contribute considerably to successful project selection.We cooperate with venture capital funds, business angels, government agencies interested in the development of biopharmaceutical industry, medical institutions and laboratories. Our many years’ experience and in-depth knowledge of the industry ecosystem provides portfolio companies with all opportunities for a quick start and establishment of effective relationships with their key partners throughout the whole period of its growth. Primer Capital co-invests in projects with leading venture capital funds and assists portfolio companies in fundraising.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Primer Capital invests in
Stages Primer Capital invests in
Countries Primer Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $2.1M–$20M
Investment Focus
Industry
- Health Care 8 (53%)
- Biotechnology 8 (53%)
- Pharmaceutical 8 (53%)
- Medical 5 (33%)
- Medical Device 3 (20%)
Stage
- Series A 4 (27%)
- Seed 3 (20%)
- Convertible Note 2 (13%)
- Venture - Series Unknown 2 (13%)
- Pre-Seed 1 (7%)
Country
- Russian Federation 5 (33%)
- United States 3 (20%)
- China 1 (7%)
- France 1 (7%)
- Israel 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
| COO | Total investments: 0 | Find email | ||
Maria Belousova
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Nelo develops a mobile application for financial transactions. It began operation on April 8, 2019, with its headquarters in Mexico City. | $20M / Series A / Oct 12, 2021 | ||
| MatriSys sees commercialization paths for its intellectual property in topical dermatology therapeutics, cosmetics, and skin care. The company’s lead live biologic therapeutic is currently in Phase I/II clinical trials targeting atopic dermatitis (commonly referred to as AD or eczema) patients. | $3M / Convertible Note / Mar 11, 2021 | ||
| Botkin.AI is a software-based platform for medical image processing and analysis based on artificial intelligence. The Company provides AI for analyzing radiograms and diagnosing the risk of tumors. The solution is based on deep machine learning. Botkin.AI significantly expands the radiologists’ ability to diagnose tumors and speeds up theprocessing of an increased flow of the patient’s clinical data without losing the quality of medical conclusions.It was founded in 2015 and is based in Moscow, Russian. | $2.1M / Series B / Dec 23, 2020 | ||
| Athira Pharma is a clinical-stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders.Athira is derived from the word Athir, the energy that reaches everyone. It captures its mission to develop therapies that can reachand positively impact everyone. | Convertible Note / Sep 04, 2020 | ||
| MatriSys sees commercialization paths for its intellectual property in topical dermatology therapeutics, cosmetics, and skin care. The company’s lead live biologic therapeutic is currently in Phase I/II clinical trials targeting atopic dermatitis (commonly referred to as AD or eczema) patients. | Seed / Oct 08, 2018 | ||
| Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $2.1M / Series A / Jan 04, 2018 | ||
| The lead asset is the monoclonal antibody based on a proprietary therapeutic platform to target CD71 selectively in the tumor microenvironment. Gemopharm’s approach mitigates potential toxicities that may occur from solicitation of non-selective complement dependent cytotoxicity (CDC) activation or addition of a toxin payload. Gemopharm hasgenerated in vivo proof-of-concept data demonstrating substantial efficacy and validating the mechanism of action of the lead candidate. The pilot toxicology has been completed without any signs of toxicity (no mortalities, clinical signs, or DLTs observed). Gemopharm envisages that its lead candidate can address a high unmet need for effective therapies for relapsed/refractory primary and secondary central nervous system (CNS) and intraocular lymphomas (IOL). | Venture - Series Unknown / Nov 24, 2017 | ||
| MT-Medicals developed a highly specific inhibitor of cytochrome P450 enzymes that demonstrate high conservation, which greatly reduces the probability of tuberculosis bacterial resistance to the new treatment. Its use significantly optimizes the existing combined treatment regimens for resistant forms of tuberculosis and supports theindividualization of such treatment.MT-Medicals is based in Hefei City, Anhui Province, China. | Venture - Series Unknown / Oct 01, 2017 | ||
| Bendit is a medical company that develops and manufactures innovative catheters based on a unique bending technology, enabling extensive steering abilities in micro diameter and conventional catheter wires and tubes. The company is a joint venture between three experienced groups from production, quality & regulation, and development in themedical field. | $3.6M / Series A / Sep 03, 2017 | ||
| Data MATRIX provides a wide range of data management and biostatistics services. With its in-house built EDC platform it specializes in data work planning, CRF design, and database customization according to study requirements. Data verification is done through both automated and manual methods, with a strict adherence to query tracking. Thecompany also provides ePRO solutions to avoid the 'parking lot effect', a situation where patients hastily fill out questionnaires right before their doctor appointments. Data MATRIX ensures personal data processing is performed in strict compliance with international and local legislation. | $2.4M / Series A / Dec 15, 2016 | ||
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Primer Capital invest in?
Primer Capital invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Seed stage. Most of the 15 investments tracked by Shizune back companies in Russian Federation. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Primer Capital invest in?
Primer Capital typically joins rounds of $2.1M–$20M at Series A. These are whole funding-round sizes, not Primer Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Primer Capital took part in.
How do I contact Primer Capital?
Public channels for Primer Capital include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Primer Capital?
The team at Primer Capital includes Elizaveta Rozhdestvenskaya (COO) and Maria Belousova (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
